ANI PHARMACEUTICALS INC
ANIPUS売上高
$883M
百万USD
営業利益
$111M
百万USD
純利益
$78M
百万USD
ROE
14.5%
最新FY
EPS
$3.32
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $55M | $0M | $0.01 |
| FY2021 | Q2 | $49M | $-14M | $-1.17 |
| FY2021 | Q3 | $52M | $-4M | $-0.37 |
| FY2021 | FY | $216M | $-43M | $-3.40 |
| FY2022 | Q1 | $64M | $-20M | $-1.27 |
| FY2022 | Q2 | $74M | $-15M | $-0.94 |
| FY2022 | Q3 | $84M | $-9M | $-0.55 |
| FY2022 | FY | $316M | $-48M | $-3.05 |
| FY2023 | Q1 | $107M | $1M | $0.06 |
| FY2023 | Q2 | $117M | $6M | $0.29 |
| FY2023 | Q3 | $132M | $10M | $0.45 |
| FY2023 | FY | $487M | $19M | $0.85 |
| FY2024 | Q1 | $137M | $18M | $0.82 |
| FY2024 | Q2 | $138M | $-2M | $-0.14 |
| FY2024 | Q3 | $148M | $-24M | $-1.27 |
| FY2024 | FY | $614M | $-19M | $-1.04 |
| FY2025 | Q1 | $197M | $16M | $0.69 |
| FY2025 | Q2 | $211M | $9M | $0.36 |
| FY2025 | Q3 | $228M | $27M | $1.13 |
| FY2025 | FY | $883M | $78M | $3.32 |
| FY2026 | Q1 | $237M | $29M | $1.28 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $202M | $207M | $208M | $216M | $316M | $487M | $614M | $883M |
| 営業利益 | $20M | $28M | $35M | $16M | $-16M | $-40M | $-35M | $47M | $1M | $111M |
| 純利益 | $4M | $-1M | $15M | $6M | $-23M | $-43M | $-48M | $19M | $-19M | $78M |
| 総資産 | $323M | $412M | $431M | $457M | $461M | $772M | $760M | $904M | $1.3B | $1.4B |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $170M | $175M | $197M | $213M | $196M | $334M | $314M | $433M | $404M | $541M |
| 営業CF | $27M | $39M | $67M | $46M | $15M | $3M | $-31M | $119M | $64M | $185M |
| EPS | $0.34 | $-0.09 | $1.30 | $0.50 | $-1.88 | $-3.40 | $-3.05 | $0.85 | $-1.04 | $3.32 |
| BPS | - | - | - | - | - | - | - | - | - | - |
| ROE | 2.3% | -0.6% | 7.9% | 2.9% | -11.5% | -12.8% | -15.3% | 4.3% | -4.6% | 14.5% |